To our full list of publications from PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=israelson+a&sort=date
Alfahel L*, Gschwendtberger T*, Kozareva V, Dumas L, Gibbs R, Kertser A, Baruch K, Zaccai S, Kahn J, Thau-Habermann N, Eggenschwiler R, Sterneckert J, Herrmann A, Rafuse V, Fraenkel E, Cantz T, Petri S and Israelson A. Targeting low levels of MIF expression as a potential therapeutic strategy for ALS. Cell Rep. Med. 5, 101546 (2024).
Zaccai S, Nemirovski A, Lerner L, Alfahel L, Eremenko E, Israelson A#, Monsonego A#. CD4 T-Cell Aging Exacerbates Neuroinflammation in a Late-Onset Mouse Model of Amyotrophic Lateral Sclerosis. J. Neuroinflammation 21, 17 (2024). (#corresponding author)
Bakavayev S, Stavsky A, Argueti-Ostrovsky S, Yehezkel G, Barak Z, Gitler D, Israelson A#, and Engel S#. Blocking an epitope of misfolded SOD1 ameliorates disease phenotype in a model of amyotrophic lateral sclerosis. Brain 146, 4594-4607 (2023). (#corresponding author)
Shteinfer-Kuzmine A*, Argueti-Ostrovsky S*, Leyton-Jaimes M, Anand U, Abu-Hamad S, Zalk R, Shoshan-Barmatz V# and Israelson A#. Targeting the mitochondrial protein VDAC1 as a potential therapeutic strategy in ALS. Int. J. Mol. Sci 23, 9946 (2022).
Alfahel L*, Argueti-Ostrovsky S*, Barel S*, Ali Saleh M, Kahn J, Azoulay-Ginsburg S, Rothstein A, Ebbinghaus S, Gruzman A and Israelson A. 4-phenylbutyric acid (4-PBA) derivatives prevent SOD1 amyloid aggregation in vitro with no effect on disease progression in SOD1-ALS mice. Int. J. Mol. Sci 23, 9403 (2022).
Alaskarov A*, Barel S*, Bakavayev S, Kahn J and Israelson A. MIF homolog d-dopachrome tautomerase (D-DT/MIF-2) does not inhibit accumulation and toxicity of misfolded SOD1 Sci. Rep. 12, 9570 (2022).
Malada Edelstein Y, Solomonov Y, Hadad N, Alfahel L, Israelson A and Levy R. Early upregulation of cytosolic Phospholipase A2α in motor neurons is induced by misfolded SOD1 in a mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 18, 274 (2021).
Argueti-Ostrovsky S*, Alfahel L*, Kahn J and Israelson A. All roads lead to Rome: Different molecular players converge to common toxic pathways in neurodegeneration. Cells 10, 2438 (2021).
Bakavayev S, Argueti S, Venkatachalam N, Yehezkel G, Stavsky A, Barak Z, Israelson A#, and Engel S#. The exposure of β6/β7-loop in Zn/Cu-superoxide dismutase (SOD1) is coupled to metal loss and is transiently reversible during misfolding. ACS Chem. Neurosci. 12, 49-62 (2021) (#corresponding author)
Leyton-Jaimes M*, Ivert P*, Han Y, Hoeber J, Zhou C, Feiler A, Pankratova S, Shoshan-Barmatz V, Israelson A#, Kozlova E#. Empty mesoporous silica particles delay disease progression and extend survival in a mouse model of ALS. Sci. Rep. 10, 20675 (2020) (#corresponding author)
Leyton-Jaimes M, Kahn J and Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset and extends survival in mouse models of inherited ALS. Proc. Natl. Acad. Sci. USA 116, 14755-14760 (2019)
Shteinfer-Kuzmine A*, Argueti S*, Gupta R*, Shvil N, Abu-Hamad S, Gropper Y, Hoeber J, Magri A, Messina A, Kozlova E, Shoshan-Barmatz V and Israelson A. A VDAC1-derived N-terminal peptide inhibits mutant SOD1-VDAC1 interactions and toxicity in the SOD1 model of ALS. Front. Cell. Neurosci. 13, 146 (2019)
Blacher E*, Bashiardes S*, Shapiro H*, Rothschild D*, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, Zabari M, Ben-Zeev Brik R, Zmora N, Cohen Y, Bar N, Levi I, Amar N, Mehlman T, Brandis A, Biton I, Kuperman Y, Tsoory M, Shental N, Alfahel L, Harmelin A, Schwartz M, Israelson A, Arike L, Johansson M, Hansson G.C., Gotkine M, Segal E, Elinav E. Potential roles of gut microbiome commensals & associated metabolites 1 in modulation of murine Amyotrophic Lateral Sclerosis. Nature 572, 474-480 (2019)
Shvil N, Banerjee V, Zoltsman G, Shani T, Kahn J, Abu-Hamad S, Papo N, Engel S, Bernhagen J and Israelson A. MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: Implications for familial ALS. Cell Death & Disease 9,107Â (2018)
Leyton-Jaimes M, Kahn J and Israelson A. Macrophage Migration Inhibitory Factor: A Multifaceted Cytokine Implicated in Multiple Neurological Diseases. Exp. Neurol. 301,83-91Â (2018)
Abu-Hamad S, Kahn J, Leyton-Jaimes M, Rosenblatt J and Israelson A. Misfolded SOD1 accumulation and mitochondrial association contribute to the selective vulnerability of motor neurons in familial ALS: correlation to human disease. ACS Chem. Neurosci. 8, 2225-2234Â (2017)
Leyton-Jaimes M*, Benaim C*, Abu-Hamad S*, Guetta A, Kahn J, Bucala R, and Israelson A. Endogenous Macrophage Migration Inhibitory Factor Reduces the Accumulation and Toxicity of Misfolded SOD1 in a Mouse Model of ALS. Proc. Natl. Acad. Sci. USA 113, 10198-10203 (2016)
Israelson A#, Ditsworth D, Sun S, Song SW, Liang J, Hruska-Plochan M, McAlonis-Downes M, Abu-Hamad S, Zoltsman G, Shani T, Maldonado M, Bui A, Navarro M, Zhou H, Marsala M, Kaspar BK, Da Cruz S and Cleveland DW#. Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD1. Neuron 86, 218-232 (2015) (# corresponding author)
Li Q*, Vande Velde C*, Israelson A, Xie J, Bailey AO, Dong M, Chun S, Roy T, Yates JR., Capaldi RA, Cleveland DW and Miller TM. ALS-linked mutant superoxide dismutase 1(SOD1) alters mitochondrial protein composition and decreases protein import. PNAS 107, 21146-21151 (2010)
Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V and Cleveland DW. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron  67, 575-587 (2010)
Google Scholar: https://scholar.google.com/citations?user=5MgUJ90AAAAJ&hl=en
PATENTS
1. Israelson A and Cleveland DW. Mif for use in methods of treating subjects with a neurodegenerative disorder. Publication number: WO2013184209 A1
(International Application Number PCT/US2013/031449) (2013).
2. Shoshan-Barmatz V, Israelson A and Lemelson D. Fluorescent Ruthenium Compounds for Detecting Calcium Binding Proteins.
(International Application Number PCT/IL2007/001210) (2007).
3. Shoshan-Barmatz V and Israelson A. Photoreactive Compound Specifically Binding to Calcium Binding Proteins.
(International Application Number PCT/IL2005/000203) (2005).
4- Shoshan-Barmatz V and Israelson A. VDAC1-derived N-terminal peptides and use thereof for treating ALS. (International Application PCT) (2019).
5- Kozlova E, Feiler A, Zhou C, Israelson A and Shoshan-Barmatz V. Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia. (International Application PCT) (2019).